Efficacy of Daratumumab Combined With Bortezomib and Dexamethasone in Patients With Mayo 04 Stage III Light Chain Amyloidosis: a Prospective Phase II Clinical Trial

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 07 May 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bortezomib (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary)
Indications Amyloid light-chain amyloidosis
Focus Therapeutic Use

12 Dec 2023 Results (N=47) assessing the efficacy and safety of low-frequency Daratumumab in patients with AL amyloidosis, were presented at the 65th American Society of Hematology Annual Meeting and Exposition.
13 Dec 2022 Results assessing the efficacy and safety of daratumumab plus bortezomib and dexamethasone in high-risk patients with Mayo 2004 stage 3 AL amyloidosis presented at the 64th American Society of Hematology Annual Meeting and Exposition
09 May 2022 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com